Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios. Money Flow Uptick/Downtick RatioMoney flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades.
The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023. Edwards Lifesciences has a short interest ratio (“days to cover”) of 3.2, which is generally considered an acceptable ratio of short interest to trading volume. In 2025, EW is forecast to generate $4,467,453,580,224 in revenue, with the lowest revenue forecast at $4,467,453,580,224 and the highest revenue forecast at $4,467,453,580,224. In 2025, EW is forecast to generate $2,019,600,475 in earnings, with the lowest earnings forecast at $2,019,600,475 and the highest earnings forecast at $2,019,600,475. Based on 17 analysts offering ratings for Edwards Lifesciences Corp.
Sign Up NowGet this delivered to your inbox, and more info about our products and services. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.
Earnings & Revenue
The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green. According to analysts’ consensus price target of $88.95, Edwards Lifesciences has a forecasted upside of 8.6% from its current price of $81.91.
EAST WEST BANKING CORPORATION
Over the previous 90 days, Edwards Lifesciences’s stock had 4 downgrades by analysts. Edwards Lifesciences’ stock is owned by a number of institutional and retail investors. https://day-trading.info/ (3.60%), Moneta Group Investment Advisors LLC (2.49%), Brown Advisory Inc. (2.32%), Geode Capital Management LLC (1.96%), Norges Bank (1.43%) and Amundi (1.31%).
EW stock cut to Hold at Stifel on TAVR market outlook (NYSE:EW) – Seeking Alpha
EW stock cut to Hold at Stifel on TAVR market outlook (NYSE:EW).
Posted: Tue, 06 Dec 2022 08:00:00 GMT [source]
Visit a quote page and your recently viewed tickers will be displayed here. Edwards Lifesciences has been rated by Canaccord Genuity Group, Morgan Stanley, Piper Sandler, Raymond James, Sanford C. Bernstein, Truist Financial, and Wells Fargo & Company in the past 90 days. 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. While overall activity for our top managers decreased again, our early read on the buying and selling activity during the period did uncover a few ideas worth considering.
One share of EW stock can currently be purchased for approximately $81.58. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Out of 17 analysts, 6 (35.29%) are recommending EW as a Strong Buy, 4 (23.53%) are recommending EW as a Buy, 7 (41.18%) are recommending EW as a Hold, 0 (0%) are recommending EW as a Sell, and 0 (0%) are recommending EW as a Strong Sell. Ownerin %Freefloat98.85Vanguard Group, Inc. 8.05State Street Corp.4.49Capital Research & Management Co. 3.74AllianceBernstein LP3.60Vanguard Total Stock Market Index Fund3.11BlackRock Fund Advisors3.10Wellington Management Co.
Short interest in Edwards Lifesciences has recently increased by 6.77%, indicating that investor sentiment is decreasing significantly. 2.12% of the float of Edwards Lifesciences has tickmill review and rating, https been sold short. Please log in to your account or sign up in order to add this asset to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.
The largest positive contribution comes from its “Physical diseases” impact, which is mostly driven by its “Catheters”, “Mitral valve repair devices”, and “Artificial heart valves” products. Edwards Lifesciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical heart valves and minimally invasive valve therapy—one of the hottest areas in cardiac devices. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services.
Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. 18 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Edwards Lifesciences in the last year.
Insider exercised options and sold US$335k worth of stock
Provide specific products and services to you, such as portfolio management or data aggregation. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Represents the company’s profit divided by the outstanding shares of its common stock.
Edwards Lifesciences has received a consensus rating of Hold. The company’s average rating score is 2.39, and is based on 8 buy ratings, 9 hold ratings, and 1 sell rating. On average, 7 Wall Street analysts forecast EW’s revenue for 2024 to be $4,107,394,706,072, with the lowest EW revenue forecast at $4,022,229,005,692, and the highest EW revenue forecast at $4,193,104,238,628. On average, 7 Wall Street analysts forecast EW’s earnings for 2024 to be $1,867,522,126, with the lowest EW earnings forecast at $1,812,773,920, and the highest EW earnings forecast at $1,934,436,599.
Top 5 4th Quarter Trades of Frank Sands
- Only 10 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days.
- High-growth stocks tend to represent the technology, healthcare, and communications sectors.
- MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues. Tech investors burned by earnings disappointments and recapitalization. Declining fuel prices stoked great returns at several of these companies, but that’s not a lasting advantage.
Edwards Lifesciences Stock Slumps on Guidance Cut
In the past three months, Edwards Lifesciences insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,902,704.00 in company stock. Edwards Lifesciences has received a 54.55% net impact score from Upright.
Net money flow is the value of uptick trades minus the value of downtick trades. According to analysts, Edwards Lifesciences’s stock has a predicted upside of 13.70% based on their 12-month price targets. Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure. Shares Sold ShortThe total number of shares of a security that have been sold short and not yet repurchased.Change from LastPercentage change in short interest from the previous report to the most recent report.